RxDoctor Payments Data

Robert Wark, MD

Clinical Cardiac Electrophysiology · Olympia, WANPI 1730181769

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by Boston Scientific at 58.2% of the total. Reporting peaked in 2019 at $2,235 and has fallen 88.5% since, to $257 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in WA, where the typical reported total is $7,912.

$3,561in general payments, 2019–2025

Across 56 payments — averaging $63.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$989
  • Abbott$196
  • Otsuka America Pharmaceutical, Inc.$99
  • Abiomed$80
  • Boehringer Ingelheim$39
  • plus $88 from 4 others

What the payments were for

  • Travel & lodging$1,82951%
  • Food & beverage$1,73249%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,561 in reported general payments places this provider in the 35th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$420,171
Medicare patients
1,087
Services billed
4,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban563$680,941
XareltoRivaroxaban157$189,465
EntrestoSacubitril/Valsartan69$70,054
Repatha SureclickEvolocumab13$10,763
MultaqDronedarone Hcl13$9,715
JardianceEmpagliflozin11$9,407
BrilintaTicagrelor15$8,665
Dabigatran EtexilateDabigatran Etexilate Mesylate26$7,728
Metoprolol Succinate483$6,858
Flecainide Acetate157$6,200
Amiodarone Hcl191$5,776
Propafenone Hcl ErPropafenone Hcl17$5,276
Atorvastatin Calcium294$3,758
Ranolazine ErRanolazine22$3,215
Digoxin129$2,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$33$189,465157 claims
NovartisEntresto$20$70,05469 claims
Boehringer IngelheimJardiance, Pradaxa$39$11,80227 claims
AstraZenecaBrilinta$16$8,66515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →